Drugs / HRS-9563
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07117474 | Dec 2024 → Dec 2025 overdue | hypertensive disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07297797 | Jan → Jul 2026 overdue | hypertensive disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-9563 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07297797 ↗ |
| Route | Subcutaneous | “A single subcutaneous injection of HRS-9563 injection or placebo was administered” NCT07117474 ↗ |